Medicine and Dentistry
Acute Myeloid Leukemia
32%
Age
12%
CDK Inhibitor
12%
Cells
7%
Chemotherapeutic Agent
33%
Chemotherapy
12%
Combination Therapy
66%
Comprehension
7%
Differentiation
7%
Diseases
26%
Drug
33%
Family
12%
Glimepiride
7%
Health Care Cost
7%
Inpatient
12%
Laboratory
12%
Malignant Transformation
7%
Morphology
12%
Neuromuscular Blocking Agent
7%
Overall Survival
12%
Pancuronium Bromide
7%
Patient
50%
Pediatric Acute Myeloid Leukemia
100%
Pediatrics Patient
12%
Precursor
7%
Prognosis
25%
Purvalanol A
12%
Screening
100%
Side Effect
12%
Survival Rate
12%
Targeted Therapy
19%
Therapeutic Procedure
64%
Vinblastine Sulfate
7%
Vinca Alkaloid
7%
Pharmacology, Toxicology and Pharmaceutical Science
Acute Myeloid Leukemia
100%
Combination Therapy
26%
Diseases
22%
Drug
28%
Glimepiride
6%
Malignant Transformation
6%
Neuromuscular Blocking Agent
6%
Overall Survival
10%
Pancuronium Bromide
6%
Preleukemia
10%
Prognosis
20%
Purvalanol A
10%
Repurposing
6%
Side Effect
10%
Survival Rate
10%
Vinblastine Sulfate
6%
Vinca Alkaloid
6%
Biochemistry, Genetics and Molecular Biology
Age
10%
Bcl-2 Family
10%
Cyclin-Dependent Kinase
10%
Genetics
10%
Morphology
10%
Myeloid
50%
Overall Survival
10%
Pediatrics
50%
Screening
50%
Survival Rate
10%
Time
10%